Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Morin, Ryan D., Assouline, Sarit, Alcaide, Miguel, Mohajeri, Arezoo, Johnston, Rebecca L., Chong, Lauren, Grewal, Jasleen, Yu, Stephen, Fornika, Daniel, Bushell, Kevin, Nielsen, Torsten Holm, Petrogiannis-Haliotis, Tina, Crump, Michael, Tosikyan, Axel, Grande, Bruno M., MacDonald, David, Rousseau, Caroline, Bayat, Maryam, Sesques, Pierre, Froment, Remi, Albuquerque, Marco, Monczak, Yury, Oros, Kathleen Klein, Greenwood, Celia, Riazalhosseini, Yasser, Arseneault, Madeleine, Camlioglu, Errol, Constantin, André, Pan-Hammarstrom, Qiang, Peng, Roujun, Mann, Koren K., Johnson, Nathalie A. · 2016 · Clinical Cancer Research

Abstract

Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of patients, and yet little is known about its biology. Experimental Design: Using exome sequencing, we characterized the mutation profiles of 38 rrDLBCL biopsies obtained at the time of progression after immunochemotherapy. To identify genes that may be associated with relapse, we compared the mutation frequency in samples obtained at relapse to an unrelated cohort of 138 diagnostic DLBCLs and separately amplified specific mutations in their matched diagnostic samples to identify clonal expansions. Results: On the basis of a higher frequency at relapse and evidence for clonal selection, TP53, FOXO1, MLL3 (KMT2C), CCND3, NFKBIZ, and STAT6 emerged as top candidate genes implicated in therapeutic resistance. We observed individual examples of clonal expansions affecting genes whose mutations had not been previously associated with DLBCL including two regulators of NF-κB: NFKBIE and NFKBIZ. We detected mutations that may be affect sensitivity to novel therapeutics, such as MYD88 and CD79B mutations, in 31% and 23% of patients with activated B-cell–type of rrDLBCL, respectively. We also identified recurrent STAT6 mutations affecting D419 in 36% of patients with the germinal center B (GCB) cell rrDLBCL. These were associated with activated JAK/STAT signaling, increased phospho-STAT6 protein expression and increased expression of STAT6 target genes. Conclusions: This work improves our understanding of therapeutic resistance in rrDLBCL and has identified novel therapeutic opportunities especially for the high-risk patients with GCB-type rrDLBCL. Clin Cancer Res; 22(9); 2290–300. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2123

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 221

Metadata

Authors
Morin, R. D., Assouline, S., Alcaide, M., Mohajeri, A., Johnston, R. L., Chong, L., Grewal, J., Yu, S., Fornika, D., Bushell, K., Nielsen, T. H., Petrogiannis-Haliotis, T., Crump, M., Tosikyan, A., Grande, B. M., MacDonald, D., Rousseau, C., Bayat, M., Sesques, P., Froment, R., Albuquerque, M., Monczak, Y., Oros, K. K., Greenwood, C., Riazalhosseini, Y., Arseneault, M., Camlioglu, E., Constantin, A., Pan-Hammarstrom, Q., Peng, R., Mann, K. K., & Johnson, N. A.
Venue
Clinical Cancer Research
Published
2016-05-01
Volume
22
Issue
9
Pages
2290-2300
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2193707124
Cited by
221
References
1
FWCI
15.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2123
The paper
Morin, R. D., Assouline, S., Alcaide, M., Mohajeri, A., Johnston, R. L., Chong, L., Grewal, J., Yu, S., Fornika, D., Bushell, K., Nielsen, T. H., Petrogiannis-Haliotis, T., Crump, M., Tosikyan, A., Grande, B. M., MacDonald, D., Rousseau, C., Bayat, M., Sesques, P., . . . Johnson, N. A. (2016). Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.